Zacks Investment Research on MSN

AC Immune (ACIU) upgraded to buy: Here's why

AC Immune (ACIU) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...
Nasdaq

AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates

AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago. These figures are ...
Zacks Investment Research on MSN

Is AC Immune (ACIU) outperforming other medical stocks this year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AC Immune (ACIU) been one of those stocks this year? A quick ...
Nasdaq

AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

The market expects AC Immune (ACIU) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2023. This widely-known consensus ...